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Abstract: BACKGROUND We compared, through the European Liver Transplant Registry, long-term
liver transplantation outcomes with prolonged-release tacrolimus (PR-T) versus immediate-release tacrolimus
(IR-T)-based immunosuppression. This retrospective analysis comprises up to 8-year data collected be-
tween 2008 and 2016, in an extension of our previously published study. METHODS Patients with
<1 month follow-up were excluded; patients were propensity score matched for baseline characteristics.
Efficacy measures included: univariate/multivariate analyses of risk factors influencing graft/patient sur-
vival up to 8 years posttransplantation, and graft/patient survival up to 4 years with PR-T versus IR-T.
Overall, 13 088 patients were included from 44 European centers; propensity score-matched analyses
comprised 3006 patients (PR-T: n = 1002; IR-T: n = 2004). RESULTS In multivariate analyses, IR-T-
based immunosuppression was associated with reduced graft survival (risk ratio, 1.49; P = 0.0038) and
patient survival (risk ratio, 1.40; P = 0.0215). There was improvement with PR-T versus IR-T in graft
survival (83% versus 77% at 4 y, respectively; P = 0.005) and patient survival (85% versus 80%; P =
0.017). Patients converted from IR-T to PR-T after 1 month had a higher graft survival rate than pa-
tients receiving IR-T at last follow-up (P < 0.001), or started and maintained on PR-T (P = 0.019). One
graft loss in 4 years was avoided for every 14.3 patients treated with PR-T versus IR-T. CONCLUSIONS
PR-T-based immunosuppression might improve long-term outcomes in liver transplant recipients than
IR-T-based immunosuppression.
DOI: https://doi.org/10.1097/TP.0000000000002700
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Background. We compared, through the European Liver Transplant Registry, long-term liver transplantation outcomes 
with prolonged-release tacrolimus (PR-T) versus immediate-release tacrolimus (IR-T)–based immunosuppression. This retro-
spective analysis comprises up to 8-year data collected between 2008 and 2016, in an extension of our previously published 
study. Methods. Patients with <1 month follow-up were excluded; patients were propensity score matched for baseline 
characteristics. Efficacy measures included: univariate/multivariate analyses of risk factors influencing graft/patient survival 
up to 8 years posttransplantation, and graft/patient survival up to 4 years with PR-T versus IR-T. Overall, 13 088 patients 
were included from 44 European centers; propensity score–matched analyses comprised 3006 patients (PR-T: n = 1002; 
IR-T: n = 2004). Results. In multivariate analyses, IR-T-based immunosuppression was associated with reduced graft sur-
vival (risk ratio, 1.49; P = 0.0038) and patient survival (risk ratio, 1.40; P = 0.0215). There was improvement with PR-T versus 
IR-T in graft survival (83% versus 77% at 4 y, respectively; P = 0.005) and patient survival (85% versus 80%; P = 0.017). 
Patients converted from IR-T to PR-T after 1 month had a higher graft survival rate than patients receiving IR-T at last follow-
up (P < 0.001), or started and maintained on PR-T (P = 0.019). One graft loss in 4 years was avoided for every 14.3 patients 
treated with PR-T versus IR-T. Conclusions. PR-T-based immunosuppression might improve long-term outcomes in liver 
transplant recipients than IR-T-based immunosuppression.
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S
ignificant advances in the success of liver transplanta-
tion have been made over the past 2 decades, despite 
the increasing use of extended criteria donors.1 However, 
although 1-year graft and patient survival rates in Europe 
are 77% and 83%, respectively, after a first liver trans-
plantation, 10-year graft and patient survival rates remain 
lower at 54% and 61%, respectively.2 Improving long-
term liver transplant outcomes has, therefore, become a 
primary focus of the transplant community. Many factors 
can negatively influence outcomes in liver transplantation, 
including high Model for End-stage Liver Disease (MELD) 
scores and the viral status of the recipient (eg, hepatitis C 
virus [HCV] infection).3,4 Nonadherence to immunosup-
pressive therapy and high intrapatient variability of drug 
exposure could also potentially reduce long-term trans-
plant outcomes.5-10
Tacrolimus is now the cornerstone of immunosuppres-
sion after liver transplantation.11 A once-daily, prolonged-
release (PR) formulation of tacrolimus was licensed in 
Europe in 2007, for use in adult kidney or liver transplant 
recipients.12 PR tacrolimus has demonstrated compara-
ble efficacy to immediate-release (IR) tacrolimus in clini-
cal studies with de novo liver transplant recipients and is 
efficacious following conversion of stable liver transplant 
recipients from IR to PR tacrolimus.13-16 However, it is 
thought that the PR formulation may offer advantages 
over twice daily, IR tacrolimus, by reducing nonadher-
ence to immunosuppressant medication and by decreasing 
intrapatient variability in tacrolimus exposure.17-19 As both 
of these parameters have been associated with poor liver 
transplant outcomes,8,20 treatment with PR tacrolimus 
has the potential to improve long-term outcomes for liver 
recipients, compared with the IR formulation. However, 
as clinical trials are of relatively short duration, there is 
a need for data to assess the effect of PR tacrolimus on 
long-term outcomes in liver transplantation. In this regard, 
registry studies can provide prospective and retrospective 
long-term data.
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The impact of PR versus IR tacrolimus on long-term 
graft and patient survival was recently assessed using data 
from the European Liver Transplant Registry (ELTR) in 
528 and 3839 patients receiving PR or IR tacrolimus, 
respectively.21 The study was conducted at 21 European 
centers between 2008 and 2012.21 Multivariable analyses 
showed that the use of IR tacrolimus was associated with 
a higher risk of graft loss (risk ratio, 1.81; P = 0.001) and 
patient death (risk ratio, 1.72; P = 0.004) compared with 
PR tacrolimus.21 We report here an analysis of up to 8-year 
data, collected between 2008 and 2016, in an extension 
of the previously published study, with the aim of com-
paring long-term liver transplant outcomes with PR versus 
IR tacrolimus–based immunosuppression. We also studied 
the outcome of converting patients from one formulation 
of the drug to the other, during the posttransplantation 
follow-up period.
MATERIALS AND METHODS
This was a retrospective analysis of primary liver trans-
plant patients receiving PR tacrolimus (Advagraf; Astellas 
Pharma Europe BV, The Netherlands) and IR tacrolimus in 
the ELTR database, as previously described.21 The ELTR 
currently represents liver transplant data from 174 trans-
plant centers across Europe. Data from participating cent-
ers are collected on a voluntary basis at regular intervals 
using a 2-part, standardized questionnaire designed by the 
ELTR Coordinating Committee to capture information on 
donors and recipients, as described previously.21 The meth-
ods used to populate the registry and obtain the data have 
been described elsewhere.22-24 To prevent center bias, only 
the 44 centers who used both PR and IR tacrolimus at the 
time of the study were eligible for inclusion in this analysis.
Inclusion Criteria
Data were collected prospectively from patients (aged 
≥18 y) who underwent their first liver transplant between 
January 2008 and June 2016 from contributing centers 
across Europe. All patients included in this study received 
PR or IR tacrolimus, with or without concomitant immu-
nosuppressants (including induction agents) within the 
first month after liver transplantation.
Clinical Efficacy Measures
Efficacy measures were analyzed using the modified 
intent-to-treat population, which excluded all patients 
who had <1 month of follow-up after transplantation. 
This strategy aimed to avoid the potential impact of 
early postoperative complications not associated with 
the immunosuppressive regimen. The clinical efficacy 
measures included univariate and multivariate analyses 
of the risk factors influencing graft and patient survival; 
Kaplan-Meier estimates of the incidence of graft and 
patient survival stratified by PR and IR tacrolimus–based 
immunosuppression, and causes of graft loss and mortal-
ity. Treatment groups were stratified by PR or IR tacroli-
mus treatment during the first month after transplantation, 
and patients remained in these allocated groups, regard-
less of any changes in immunosuppression during follow-
up. However, crossover changes from IR to PR and vice 
versa after 1 month of therapy, regardless of the date of 
change(s), were considered to measure their impact on 
graft and patient outcomes. The maintenance immuno-
suppression data considered in this study were those col-
lected at the last patient follow-up. The number of patients 
needed to treat with PR versus IR tacrolimus to avoid 1 
graft loss in 4 years was calculated. To adjust for the num-
ber of patients at risk over the enrollment time between 
2008 and 2016 (fewer patients at risk in the PR than IR 
tacrolimus group at 4 y owing to the gradual increase in 
the use of PR tacrolimus), the era of transplantation was 
added to the univariate and multivariate analyses.
Propensity Score Matching
To account for differences in donor and recipient base-
line characteristics between groups when estimating the 
effect of treatment on outcomes, the clinical efficacy meas-
ures were repeated on a propensity score–matched popu-
lation. PR and IR tacrolimus groups were paired on a 1:2 
ratio according to 18 items with similar values. The pro-
pensity score was based on recipient age (≥60 versus <60 
y), donor age (≥60 versus <60 y), full-size organ from a 
donor after brain death versus all other alternative grafts 
(living donor, domino, donation after circulatory death, 
or split grafts from a donor after brain death), MELD 
score (>24 versus ≤24), recipient hepatitis B virus (HBV) 
surface antigen, hepatocellular carcinoma (HCC), pres-
ence of severe ascites before liver transplantation, United 
Network for Organ Sharing (UNOS) status (3–4 versus 
1–2), total ischemia time (≥6 versus <6 h), graft preserva-
tion solution histidine-tryptophan-ketoglutarate versus 
all other solutions (University Wisconsin, Celsior, IGL-1, 
Marshall, Ringer, Solution de conservation des Organes et 
des Tissus [SCOT], or other), and administration of other 
immunosuppressive medications early posttransplantation 
(corticosteroids, mycophenolate mofetil, ciclosporin, basi-
liximab, daclizumab, sirolimus, everolimus, azathioprine). 
For continuous variables that were converted to discontin-
uous variables in the model (eg, donor age, recipient age, 
MELD score), the values that were the most discriminant 
between PR and IR tacrolimus were selected as cutoffs, 
based on the calculation of chi-square value and odds 
ratios (data not shown). All unmatched units in the PR and 
IR tacrolimus groups were excluded from the propensity 
score–matched population.
Statistical Analyses
Statistical analyses were conducted as previously 
described.21 A univariate Cox regression analysis was per-
formed to evaluate the risk factors influencing graft and 
patient survival after liver transplantation. Data from the 
univariate analyses were reported using log-rank P values, 
with P < 0.05 considered to be statistically significant. A 
Cox proportional hazards regression evaluation (P < 0.15) 
was used in a multivariate model to assess the impact of 
donor and recipient variables on graft and patient survival. 
Patients with missing data on the ELTR questionnaire were 
excluded from the multivariate analyses. Kaplan-Meier 
analyses were used to estimate graft and patient survival 
stratified by treatment group; statistical analyses were per-
formed using the log-rank test (P < 0.05). Analyses were 
performed using SAS Enterprise Guide version 5.1 (SAS 
Institute, Inc., Cary, NC).
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RESULTS
Donor and Recipient Characteristics and 
Demographics
Patient Population
In the initial ELTR study, 4367 primary liver trans-
plant recipients (PR tacrolimus: n = 528; IR tacrolimus: 
n = 3839) were included in the analysis, between 2008 and 
2012.21 In this extension analysis, 13 088 primary liver 
transplant recipients were included (Figure 1). All patients 
received either PR tacrolimus (n = 1762) or IR tacrolimus 
(n = 11 326). Since PR tacrolimus was licensed for use in 
2007,12 the proportion of patients who received PR tac-
rolimus during month 1 gradually increased over enroll-
ment (between 2008 and 2016).
Baseline Characteristics
Baseline characteristics of donors and recipients are pre-
sented in Table 1. Mean recipient age was greater in the PR 
versus IR tacrolimus group (52.1 ± 18.7 versus 51.8 ± 18.1 
y, respectively; P < 0.001). The other main characteristics 
and their differences between groups are shown in Table 1.
Concomitant Medications
Baseline tacrolimus-associated induction immunosup-
pressive medications were different in the 2 groups: cor-
ticosteroids (69.2% versus 61.4%; P < 0.001), everolimus 
(7.5% versus 2.5%; P < 0.001), mycophenolate mofetil 
(75.1% versus 55.8%; P < 0.001), and daclizumab (1.8% 
versus 0.8%; P < 0.001) were more frequently combined 
with PR tacrolimus. Azathioprine (3.2% versus 0.5%; 
P < 0.001), ciclosporin (1.6% versus 0.2%; P < 0.001), 
basiliximab 25.4% versus 22.0%; P = 0.002), and siroli-
mus (0.6% versus 0.2%; P = 0.026) were more frequently 
combined with IR tacrolimus. However, propensity score 
matching has been used to account for these baseline dif-
ferences in our study.
Analyses of Patients With ≥1 Month of Follow-up
Univariate Analyses
In the univariate analysis, IR tacrolimus during the 
first month posttransplantation was identified as a signifi-
cant risk factor for inferior graft survival (P < 0.001) and 
patient survival (P = 0.003) over 8 years. Other factors 
that significantly contributed to reduced long-term graft 
and patient survival are listed in Table 2.
Kaplan-Meier Analyses
Kaplan-Meier analysis demonstrated significantly 
improved graft and patient survival over 4 years with PR 
versus IR tacrolimus (84% versus 79%; P < 0.001 and 
85% versus 81%; P = 0.003, respectively) (Figure 2). At 
year 4, a 5% and 4% improvement in graft and patient 
survival, respectively, was observed in the PR versus IR 
tacrolimus group.
Propensity Score–matched Analyses
The propensity score–matched analysis was performed 
on 3006 patients (PR tacrolimus: n = 1002; IR tacrolimus: 
n = 2004). Donor and recipient baseline characteristics 
were generally comparable between the 2 treatment groups 
for the propensity score–matched patients, especially for 
the concomitant immunosuppressive drugs combined with 
tacrolimus (Table 1).
Univariate and Multivariate Analyses
In the univariate analysis, the use of IR tacrolimus was 
a significant risk factor for reduced graft and patient sur-
vival (P = 0.005 and P = 0.017, respectively) in addition to 
other factors listed in Table 3. Long-term graft survival was 
significantly impacted by 13 additional factors: donor age 
≥50 years (P < 0.001), recipient age ≥50 years (P = 0.006), 
recipient dialysis twice in week before transplantation 
(P = 0.016), negative HBV delta (P = 0.017), positive anti-
HCV serology (P < 0.001), positive human immunodefi-
ciency virus serology (P = 0.028), positive HCV RNA (P < 
0.001), urgent liver transplant (P = 0.038), UNOS status 
1 or 2 (P < 0.001), serum creatinine concentration ≥2 mg/
dL (P = 0.01), Milan criteria-out in patients with HCC (P 
< 0.001), HCC with tumor size >50 mm (P < 0.001), and 
heterotopic liver transplant (P = 0.003).
Long-term patient survival was significantly impacted 
by 15 other factors: donor age ≥50 years (P < 0.001), pres-
ence of macro/microvesicular graft steatosis (P = 0.039), 
male recipient (P = 0.021), recipient age ≥50 years 
(P = 0.001), recipient dialysis twice in week before transplan-
tation (P = 0.006), negative HBV delta (P = 0.025), positive 
anti-HCV serology (P < 0.001), positive human immuno-
deficiency virus serology (P = 0.045), positive HCV RNA (P 
< 0.001), UNOS status 1 or 2 (P < 0.001), serum creatinine 
concentration ≥2 mg/dL (P = 0.001), cancer as main indica-
tion (P = 0.032), Milan criteria-out in patients with HCC 
(P < 0.001), HCC with tumor size >50 mm (P < 0.001), 
and heterotopic liver transplant (P = 0.001).
In the multivariate analysis (Table  4), the use of IR 
tacrolimus was a significant independent risk factor for 
reduced graft survival (risk ratio: 1.49; 95% confidence 
interval [CI]: 1.14-1.96; P = 0.0038) associated with 5 
other factors: recipient positive anti-HCV serology (risk 
ratio: 2.05; 95% CI: 1.66-2.54; P < 0.001), recipient age 
≥50 years (risk ratio: 1.74; 95% CI: 1.43-2.11; P < 0.001), 
UNOS status 1 or 2 (risk ratio: 1.69; 95% CI: 1.35-2.11; 
P < 0.001), serum creatinine concentration ≥2 mg/dL (risk 
ratio: 1.66; 95% CI: 1.18-2.35; P = 0.004), and donor age 
≥50 years (risk ratio: 1.35; 95% CI: 1.09-1.66; P = 0.005).
The use of IR tacrolimus was also a significant independ-
ent risk factor for reduced patient survival (risk ratio, 1.40; 
95% CI, 1.05-1.86; P = 0.0215) associated with 6 other 
factors: recipient positive anti-HCV serology (risk ratio, 
FIGURE 1. Patient populations. *Analysis only in centers using 
prolonged-release (PR) tacrolimus and immediate-release (IR) 
tacrolimus. †Propensity score matching ratio 1:2, PR tacrolimus/
IR tacrolimus. mITT, modified intent to treat.






























































Baseline characteristics of donors and liver transplant recipients
Parameter Category
mITT population Propensity score–matched patientsa
PR tacrolimus (n = 1762)b IR tacrolimus (n = 11 326)b Pc PR tacrolimus (n = 1002)b IR tacrolimus (n = 2004)b Pc
Donor characteristics
Mean (SD) age, y  52.1 (18.7) (n = 1743) 51.8 (18.1) (n = 11 018) 0.49 53.0 (18.7) 53.5 (18.7) 0.56
≥60, n (%) 666 (38.2) 3923 (35.6) 0.035 401 (40.0) 806 (40.2) 0.92
≥65, n (%) 486 (27.9) 2933 (26.6) 0.27 294 (29.3) 631 (31.5) 0.23
≥75, n (%) 198 (11.4) 1188 (10.8) 0.47 135 (13.5) 284 (14.2) 0.60
Sex, n (%)        
 Female 754 (43.3) 4874 (44.5) 0.34 449 (45.0) 876 (44.0) 0.57
Male 987 (56.7) 6072 (55.5) 548 (55.0) 1117 (56.0)
Recipient characteristics        
Age at first transplant (y) Mean (SD) 53.7 (11.2) 52.3 (11.6) <0.001 53.1 (11.4) 53.3 (10.8) 0.68
≥60, n (%) 584 (33.1) 3176 (28) <0.001 308 (30.7) 603 (30.1) 0.72
≥65, n (%) 242 (13.7) 1169 (10.3) <0.001 115 (11.5) 223 (11.1) 0.78
≥70, n (%) 31 (1.8) 135 (1.2) 0.048 22 (2.2) 22 (1.1) 0.018
Sex, n (%) Female 571 (32.4) 3783 (33.4) 0.41 328 (32.7) 623 (31.1) 0.36
Male 1191 (67.6) 7542 (66.6) 674 (67.3) 1381 (68.9)
Mean (SD) BMI, kg/m
2  25.9 (4.7) (n = 1660) 25.9 (4.8) (n = 10 714) 0.97 25.8 (4.8) (n = 970) 25.6 (4.5) (n = 1934) 0.20
Recipient health status and indication for 
transplant
       
HBsAg, n (%) Negative 1486 (91.1) 9130 (87.9) <0.001 908 (90.6) 1810 (90.3) 0.79
Positive 146 (8.9) 1261 (12.1) 94 (9.4) 194 (9.7)
HBV DNA, n (%) Negative 422 (92.3) 3613 (89.7) 0.079 316 (92.7) 605 (92.2) 0.80
Positive 35 (7.7) 413 (10.3) 25 (7.3) 51 (7.8)
Coexisting HBV and delta virus, n (%) Negative 316 (91.9) 1956 (87.3) 0.016 202 (92.7) 373 (86.9) 0.029
Positive 28 (8.1) 284 (12.7) 16 (7.3) 56 (13.1)
Anti-HCV serology, n (%) Negative 1230 (76.1) 7798 (75.3) 0.48 762 (77.4) 1431 (72.9) 0.008
Positive 387 (23.9) 2564 (24.7) 222 (22.6) 532 (27.1)
HCV RNA, n (%) Negative 292 (61.9) 2699 (66.8) 0.03 217 (63.8) 466 (63.2) 0.85
Positive 180 (38.1) 1339 (33.2) 123 (36.2) 271 (36.8)
HIV serology, n (%) Negative 1179 (98.1) 9821 (98.5) 0.24 825 (97.7) 1805 (98.6) 0.12
Positive 23 (1.9) 147 (1.5) 19 (2.3) 26 (1.4)
Main indication for transplant, n (%) Acute liver disease 111 (6.4) 631 (5.8) <0.001 62 (6.3) 80 (4.1) 0.046
Malignant tumors 501 (28.8) 2637 (24.0) 246 (24.9) 511 (25.9)
Chronic liver disease 1004 (57.7) 6694 (61.0) 600 (60.7) 1224 (62.1)
Benign tumors 45 (2.6) 244 (2.2) 27 (2.7) 36 (1.8)
Metabolic diseases 64 (3.7) 583 (5.3) 46 (4.7) 95 (4.8)
Other 16 (0.9) 178 (1.6) 8 (0.8) 26 (1.3)
HCC (primary or secondary disease), n (%) No 1210 (69.1) 8163 (72.5) 0.003 715 (71.4) 1397 (69.7) 0.35






















































































mITT population Propensity score–matched patientsa
PR tacrolimus (n = 1762)b IR tacrolimus (n = 11 326)b Pc PR tacrolimus (n = 1002)b IR tacrolimus (n = 2004)b Pc
Liver transplant urgencyd, n (%) Yes 99 (7.0) 701 (7.7) 0.35 65 (9.1) 99 (7.0) 0.093
No 1309 (93.0) 8346 (92.3)  651 (90.9) 1311 (93.0)  
UNOS statuse, n (%) 1 110 (6.7) 1026 (9.7) <0.001 77 (7.7) 170 (8.5) 0.76
2 176 (10.7) 1505 (14.2) 141 (14.1) 272 (13.6)
3 765 (46.4) 5848 (55.0) 594 (59.3) 1162 (58.0)
4 596 (36.2) 2245 (21.1) 190 (19.0) 400 (20.0)
Mean (SD) MELD score  17.1 (8.5) (n = 1725) 17.9 (9.0) (n = 11 040) <0.001 17.6 (8.9) 17.6 (8.8) 0.97
Liver function and baseline laboratory values        
Child-Pugh class, n (%) A 100 (16.2) 899 (14.1) 0.085 73 (16.6) 165 (16.1) 0.82
B 279 (45.1) 3166 (49.6) 203 (46.2) 492 (48.0)
C 240 (38.8) 2322 (36.4) 163 (37.1) 367 (35.8)
Mean (SD) serum creatinine concentration, 
mg/dL
 1.1 (1.5) (n = 1742) 1.2 (3.8) (n = 11 078) 0.23 1.1 (1.8) (n = 999) 1.1 (0.9) (n = 1993) 0.97
Mean (SD) total bilirubin, mg/dL  5.7 (8.2) (n = 1718) 6.2 (9.0) (n = 11 038) 0.032 6.1 (8.6) (n = 999) 5.9 (8.7) (n = 1999) 0.44
Preservation solution, n (%) HTK 816 (47.1) 3059 (28.0) <0.001 380 (37.9) 691 (34.5) 0.063
Other 915 (52.9) 7863 (72.0)  622 (62.1) 1313 (65.5)
Induction immunosuppressive regimen        
Corticosteroids, n (%) Yes 1219 (69.2) 6959 (61.4) <0.001 777 (77.5) 1579 (78.8) 0.43
No 543 (30.8) 4367 (38.6) 225 (22.5) 425 (21.2)
Azathioprine, n (%) Yes 9 (0.5) 358 (3.2) <0.001 7 (0.7) 7 (0.3) 0.18
No 1753 (99.5) 10 968 (96.8) 995 (99.3) 1997 (99.7)
Ciclosporin, n (%) Yes 4 (0.2) 180 (1.6) <0.001 4 (0.4) 10 (0.5) 0.70
No 1758 (99.8) 11 146 (98.4) 998 (99.6) 1994 (99.5)
Everolimus, n (%) Yes 133 (7.5) 280 (2.5) <0.001 49 (4.9) 128 (6.4) 0.10
No 1629 (92.5) 11 046 (97.5) 953 (95.1) 1876 (93.6)
Basiliximab, n (%) Yes 387 (22.0) 2875 (25.4) 0.002 274 (27.3) 518 (25.8) 0.38
No 1375 (78.0) 8451 (74.6) 728 (72.7) 1486 (74.2)
Sirolimus, n (%) Yes 3 (0.2) 66 (0.6) 0.026 1 (0.1) 1 (0.0) 0.62
No 1759 (99.8) 11 260 (99.4) 1001 (99.9) 2003 (100.0)
MMF, n (%) Yes 1323 (75.1) 6316 (55.8) <0.001 762 (76.0) 1504 (75.0) 0.55
No 439 (24.9) 5010 (44.2) 240 (24.0) 500 (25.0)
Daclizumab, n (%) Yes 31 (1.8) 87 (0.8) <0.001 23 (2.3) 47 (2.3) 0.93
No 1731 (98.2) 11 239 (99.2) 979 (97.7) 1957 (97.7)
Mean (SD) length of follow-up, mo  25.6 (21.1) 31.5 (26.0) <0.001 24.4 (19.9) 33.7 (25.4) <0.001
aPropensity score matching was based on recipient age (≥60 vs <60 y), donor age (≥60 vs <60 y), full-size organ from a donor after brain death vs all other alternative grafts (living donor, domino, donation after circulatory death, or split grafts from a donor after brain death), MELD 
score (>24 vs ≤24), recipient hepatitis B virus surface antigen, HCC, presence of severe ascites before liver transplantation, UNOS status (3–4 vs 1–2), total ischemia time (≥6 vs <6 h), graft preservation solution HTK versus all other solutions (University Wisconsin, Belzer, Celsior, 
IGL-1, Marshall, Ringer, Solution de conservation des Organes et des Tissus [SCOT], or other), and administration of other immunosuppressive medications early posttransplantation (corticosteroids, MMF, ciclosporin, basiliximab, daclizumab, sirolimus, everolimus, azathioprine).
bData were not available for all patients; therefore, percentages are calculated based on available data.
c
P value between treatment cohort comparisons.
dLiver transplant urgency was determined by the treating physician and indicated on the questionnaire by “yes” or “no” tick box.
eUNOS status: 1. Hospitalized in the intensive care unit, 2. Continuous hospitalization, 3. Continuous medical care, 4. At home with normal function.
BMI, body mass index; HBsAg, hepatitis B virus surface antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HTK, histidine–tryptophan-ketoglutarate; IR, immediate release; MELD, Model for End-stage Liver 
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TABLE 2.
Univariate analyses of risk factors for reduced graft and patient survival 1, 2, and 4 y posttransplantation, after exclusion 
of patients with <1 mo of follow-up (mITT population)
Parameters at first transplantation Category n
Survival, %
P
a1 y 2 y 4 y
Graft survival
Immunotherapy during mo 1 PR tacrolimus 1762 93 89 84 <0.001
IR tacrolimus 11 326 91 86 79
Donor characteristics
Donor sex Female 5628 91 86 79 0.51
Male 7059 91 87 79
Donor age ≥50 y Yes 7272 90 85 77 <0.001
No 5488 93 89 83
Donor age ≥60 y Yes 4589 90 84 76 <0.001
No 8171 92 88 81
Macro/microvesicular graft steatosis No 3286 93 89 82 0.11
Yes 2947 91 88 80
Blood group compatibility Compatible 794 88 83 77 <0.001
Isogroup 11 983 91 87 80
Noncompatible 113 77 72 59
Recipient characteristics
Recipient sex Female 4354 92 88 81 <0.001
Male 8733 91 86 78
Recipient age ≥50 y Yes 8693 90 86 78 <0.001
No 4395 92 89 82
Recipient age ≥60 y Yes 3760 89 85 77 <0.001
No 9328 92 88 81
Recipient dialysis (twice in week prior) Yes 442 81 78 71 <0.001
No 11 177 92 87 80
Recipient viral status
HBsAg Negative 10 616 91 87 79 0.008
Positive 1407 94 88 83
Coexisting HBV and delta virus Negative 2272 90 85 79 0.001
Positive 312 96 93 91
Anti-HCV serology Negative 9028 92 89 82 <0.001
Positive 2951 88 82 72
HIV serology Negative 11 000 91 87 80 <0.001
Positive 170 82 71 61
HCV RNA Negative 2991 92 88 83 <0.001
Positive 1519 88 83 71
Criteria for liver transplant
Liver transplant urgency
b Yes 800 89 86 81 0.74
 No 9655 91 87 80  
UNOS statusc 1 1136 87 83 77 <0.001
2 1681 88 84 78
3 6613 92 88 80
4 2841 93 88 80
UNOS statusc 1 or 2 Yes 2817 87 84 78 <0.001
No 9454 92 88 80
MELD score ≤14 5571 93 87 79 <0.001
15–25 4938 92 88 82
>25 2256 87 83 76
Liver function and laboratory values
Recipient Child-Pugh class A 999 92 88 79 0.1
B 3445 94 90 82
C 2562 91 88 80
Serum creatinine concentration ≥2 mg/dL Yes 906 83 79 73 <0.001
No 11 914 92 88 80
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TABLE 2. (Continued)
Parameters at first transplantation Category n
Survival, %
P
a1 y 2 y 4 y
Indication
Main indication for transplant Acute liver failure 742 90 86 81 <0.001
Chronic liver disease 7698 91 87 80
Metabolic disease 647 90 87 80
Tumor (benign) 289 94 92 88
Tumor (malignant) 3138 92 85 76
Other 194 87 83 79
Acute liver failure as main disease Yes 725 90 86 81 0.2
No 12 282 91 87 79
Cirrhosis as main disease Yes 6935 91 87 80 0.9
No 6072 91 86 79
Cancer as main disease Yes 3133 92 85 76 <0.001
No 9874 91 87 81
Milan criteria (in patients with HCC) Yes 1613 93 88 81 <0.001
No 808 87 76 61
HCC with tumor size >50 mm Yes 214 82 65 48 <0.001
No 2228 91 86 76
Surgical procedure
Total ischemia time, h >15 103 90 88 83 0.25
12–15 623 89 84 78
6–12 8325 91 87 79
0–6 2409 92 86 80
Total ischemia time ≥12 h Yes 726 89 85 78 0.53
No 10 734 91 87 79
Type of graft Full size (donor brain death) 11 390 91 87 79 0.4
Domino 89 91 84 70
Living 520 91 83 75
Reduced 36 88 88 88
Split 526 90 88 82
 After circulatory death 486 93 87 80  
Liver transplant Heterotopic 15 100 88 72 0.67
Orthotopic 12 424 91 87 80
Patient survival
Immunotherapy during mo 1 PR tacrolimus 1762 94 90 85 0.003
IR tacrolimus 11 319 92 88 81
Donor characteristics
Donor sex Female 5623 92 88 81 0.48
Male 7057 92 88 82
Donor age ≥50 y Yes 7268 91 87 79 <0.001
No 5485 94 90 85
Donor age ≥60 y Yes 4587 91 86 78 <0.001
No 8166 93 89 84
Macro/microvesicular graft steatosis No 3284 94 91 85 0.01
Yes 2943 92 89 82
Blood group compatibility Compatible 793 89 84 78 <0.001
Isogroup 11 977 92 89 82
Noncompatible 113 80 77 63
Recipient characteristics
Recipient sex Female 4353 93 90 84 <0.001
Male 8727 92 88 81
Recipient age ≥50 y Yes 8689 91 87 80 <0.001
No 4392 94 91 85
Recipient age ≥60 y Yes 3758 90 86 78 <0.001
No 9323 93 89 83
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TABLE 2. (Continued)
Parameters at first transplantation Category n
Survival, %
P
a1 y 2 y 4 y
Recipient dialysis (twice in week prior) Yes 442 82 79 74 <0.001
No 11 170 93 89 83
Recipient viral status
HBsAg Negative 10 612 92 88 82 0.007
Positive 1406 95 90 85
Coexisting HBV and delta virus Negative 2272 91 86 80 <0.001
Positive 312 96 94 92
Anti-HCV serology Negative 9023 93 90 84 <0.001
Positive 2949 89 84 75
HIV serology Negative 10 995 93 89 82 <0.001
Positive 169 82 74 64
HCV RNA Negative 2991 93 90 85 <0.001
Positive 1518 90 84 74
Criteria for liver transplant
Liver transplant urgency
b Yes 800 90 88 86 0.43
No 9648 93 89 82  
UNOS statusc 1 1135 88 85 81 <0.001
2 1680 89 85 80
3 6612 94 90 82
4 2837 94 90 83
UNOS statusc 1 or 2 Yes 2815 88 85 80 <0.001
No 9449 94 90 83
MELD score ≤14 5569 94 89 81 <0.001
15–25 4934 93 90 84
>25 2255 88 85 79
Liver function and laboratory values
Recipient Child-Pugh class A 999 95 90 82 0.05
B 3442 95 91 85
C 2560 92 89 84
Serum creatinine concentration ≥2 mg/dL Yes 905 84 80 75 <0.001
No 11 908 93 89 82
Indication
Main indication for transplant Acute liver failure 742 90 87 85 <0.001
Chronic liver disease 7694 92 89 82
Metabolic disease 647 91 88 82
Tumor (benign) 289 95 94 91
Tumor (malignant) 3138 93 86 77
Other 194 89 86 80
Acute liver failure as main disease Yes 725 90 87 85 0.16
No 12 275 92 88 81
Cirrhosis as main disease Yes 6931 92 89 82 0.63
No 6069 93 88 81
Cancer as main disease Yes 3133 93 86 77 <0.001
No 9867 92 89 83
Milan criteria (in patients with HCC) Yes 1613 94 89 83 <0.001
No 808 88 77 62
HCC with tumor size >50 mm Yes 214 82 66 50 <0.001
No 2228 93 87 78
Total ischemia time, h >15 103 90 88 85 0.59
12–15 622 91 87 81
6–12 8319 92 89 82
0–6 2409 93 88 82
Total ischemia time ≥12 h Yes 725 91 87 81 0.94
No 10 728 92 88 82
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FIGURE 2. Kaplan-Meier analyses of (A) graft and (B) patient survival over 4 y of treatment with prolonged-release (PR) tacrolimus 
compared with immediate-release (IR) tacrolimus, after exclusion of patients with <1 mo of follow-up (modified intent-to-treat population).
TABLE 2. (Continued)
Parameters at first transplantation Category n
Survival, %
P
a1 y 2 y 4 y
Type of graft Full size (donor brain death) 11 387 92 88 81 0.005
Domino 89 91 87 73
Living 520 92 84 78
Reduced 36 100 96 96
Split 526 93 90 86
After circulatory death 482 96 91 85  
Liver transplant Heterotopic 15 100 88 72 0.5
Orthotopic 12 417 92 89 82
aLog-rank P value for effect over 8 y.
bLiver transplant urgency was determined by the treating physician and indicated on the questionnaire by “yes” or “no” tick box.
cUNOS status: 1. Hospitalized in the intensive care unit, 2. Continuous hospitalization, 3. Continuous medical care, 4. At home with normal function.
HBsAg, hepatitis B virus surface antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HTK, histidine–tryptophan-ketoglutarate; IR, 
immediate release; MELD, Model for End-stage Liver Disease; mITT, modified intent to treat; MMF, mycophenolate mofetil; PR, prolonged release; UNOS, United Network for Organ Sharing.
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TABLE 3.
Univariate analyses of risk factors for reduced graft and patient survival for propensity score–matched patients
Parameters at first transplant Category n
Survival, %
P
a1 y 2 y 4 y
Graft survival
Immunotherapy during mo 1 PR tacrolimus 1002 93 89 83 0.005
IR tacrolimus 2004 90 86 77
Donor characteristics
Donor sex Female 1325 92 87 79 0.55
Male 1665 91 88 80
Donor age ≥50 y Yes 1776 90 85 76 <0.001
No 1230 93 90 84
Donor age ≥60 y Yes 1207 90 84 75 <0.001
No 1799 92 89 82
Macro/microvesicular graft steatosis No 597 93 90 81 0.069
Yes 604 90 86 77
Blood group compatibility Compatible 182 85 81 74 0.19
Isogroup 2799 92 88 79
Noncompatible 23 85 77 77
Recipient characteristics
Recipient sex Female 951 92 88 80 0.064
Male 2055 91 87 78
Recipient age ≥50 y Yes 2065 91 86 77 0.006
No 941 93 89 83
Recipient age ≥60 y Yes 911 90 85 76 0.016
No 2095 92 88 80
Recipient dialysis twice in week before 
transplantation
Yes 124 83 77 73 0.016
No 2685 92 88 79
Recipient viral status
HBsAg Negative 2718 91 87 79 0.37
Positive 288 93 88 83
Coexisting HBV and delta virus Negative 575 89 84 73 0.017
Positive 72 98 95 95
Anti-HCV serology Negative 2193 92 89 83 <0.001
Positive 754 88 82 67
HIV serology Negative 2630 91 87 79 0.028
Positive 45 91 76 66
HCV RNA Negative 683 91 87 84 <0.001
Positive 394 88 80 63
Criteria for liver transplant
Liver transplant urgency
b Yes 164 84 81 79 0.038
No 1962 92 88 80  
UNOS statusc 1 247 88 83 80 <0.001
2 413 84 79 73
3 1756 93 89 81
4 590 93 89 77
UNOS statusc 1 or 2 Yes 660 86 81 75 <0.001
No 2346 93 89 80
MELD score ≤14 1326 93 88 77 0.47
15–25 1159 91 87 81
>25 521 89 85 79
Liver function and laboratory values
Recipient Child-Pugh class A 238 94 90 82 0.37
B 695 93 90 81
C 530 90 86 79
Serum creatinine concentration ≥2 mg/dL Yes 185 87 80 74 0.01
No 2807 92 88 80
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TABLE 3. (Continued)
Parameters at first transplant Category n
Survival, %
P
a1 y 2 y 4 y
Indication
Main indication for transplant Acute liver failure 142 89 85 85 0.45
Chronic liver disease 1824 91 88 80
Metabolic disease 141 89 86 78
Tumor (benign) 63 95 88 84
Tumor (malignant) 757 93 86 75
Other 34 85 85 79
Acute liver failure as main disease Yes 140 89 85 85 0.33
No 2866 92 87 79
Cirrhosis as main disease Yes 1648 91 88 79 0.86
No 1358 92 87 79
Cancer as main disease Yes 756 93 86 75 0.1
No 2250 91 88 80
Milan criteria (in patients with HCC) Yes 550 93 87 79 <0.001
No 224 88 79 60
HCC with tumor size >50 mm Yes 63 83 65 46 <0.001
No 715 92 86 76
Surgical procedure
Total ischemia time, h >15 17 82 82 82 0.39
12–15 128 84 79 78
6–12 2186 91 87 79
0–6 675 93 88 81
Total ischemia time ≥12 h Yes 145 84 80 78 0.47
No 2861 92 88 79
Type of graft Full size (donor brain death) 2712 91 87 79 0.65
Domino 28 93 85 65
Living 77 87 83 83
Reduced 13 92 92 92
Split 116 93 92 85
After circulatory death 60 94 87 87  
Liver transplant Heterotopic 4 100 67  0.003
Orthotopic 2857 92 87 79
Patient survival
Immunotherapy during mo 1 PR tacrolimus 1002 94 90 85 0.017
IR tacrolimus 2004 92 88 80
Donor characteristics
Donor sex Female 1325 92 87 80 0.18
Male 1665 93 89 83
Donor age ≥50 y Yes 1776 91 86 78 <0.001
No 1230 94 92 86
Donor age ≥60 y Yes 1207 92 86 77 <0.001
No 1799 93 90 84
Macro/microvesicular graft steatosis No 597 93 91 85 0.039
Yes 604 92 88 78
Blood group compatibility Compatible 182 85 81 75 0.11
Isogroup 2799 93 89 82
Noncompatible 23 90 83 83
Recipient characteristics
Recipient sex Female 951 93 90 83 0.021
Male 2055 92 88 80
Recipient age ≥50 y Yes 2065 92 88 79 0.001
No 941 93 90 86
Recipient age ≥60 y Yes 911 91 86 77 0.001
No 2095 93 89 83
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TABLE 3. (Continued)
Parameters at first transplant Category n
Survival, %
P
a1 y 2 y 4 y
Recipient dialysis (twice in week prior) Yes 124 83 77 73 0.002
No 2685 93 89 82
Recipient viral status
HBsAg Negative 2718 92 88 81 0.3
Positive 288 94 90 85
Coexisting HBV and delta virus Negative 575 90 85 76 0.025
Positive 72 98 95 95
Anti-HCV serology Negative 2193 93 90 84 <0.001
Positive 754 89 83 71
HIV serology Negative 2630 92 88 81 0.045
Positive 45 91 80 70
HCV RNA Negative 683 92 89 85 <0.001
Positive 394 88 81 67
Criteria for liver transplant
Liver transplant urgency
b Yes 164 84 84 81 0.099
 No 1962 93 89 82  
UNOS statusc 1 247 89 85 82 <0.001
2 413 85 81 74
3 1756 94 90 83
4 590 94 90 80
UNOS statusc 1 or 2 Yes 660 87 83 77 <0.001
No 2346 94 90 82
MELD score ≤14 1326 94 89 79 0.22
15–25 1159 92 89 84
>25 521 90 86 80
Liver function and laboratory values
Recipient Child-Pugh class A 238 96 91 84 0.27
B 695 94 91 83
C 530 90 87 81
Serum creatinine concentration ≥2 mg/dL Yes 185 88 80 75 0.001
No 2807 93 89 82
Indication
Main indication for transplant Acute liver failure 142 90 87 87 0.24
Chronic liver disease 1824 92 89 82
Metabolic disease 141 90 87 78
Tumor (benign) 63 95 92 89
Tumor (malignant) 757 93 87 77
Other 34 91 91 85
Acute liver failure as main disease Yes 140 90 87 87 0.34
No 2866 92 88 81
Cirrhosis as main disease Yes 1648 92 89 82 0.61
No 1358 93 88 81
Cancer as main disease Yes 756 93 87 77 0.032
No 2250 92 89 83
Milan criteria (in patients with HCC) Yes 550 94 88 81 <0.001
No 224 89 80 62
HCC with tumor size >50 mm Yes 63 83 66 48 <0.001
No 715 93 87 78
Total ischemia time, h >15 17 82 82 82 0.31
12–15 128 85 80 79
6–12 2186 92 89 81
0–6 675 94 90 83
Total ischemia time ≥12 h Yes 145 85 80 79 0.26
No 2861 93 89 81
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TABLE 3. (Continued)
Parameters at first transplant Category n
Survival, %
P
a1 y 2 y 4 y
Type of graft Full size (donor brain death) 2712 92 88 81 0.57
Domino 28 93 89 69
Living 77 89 89 89
Reduced 13 100 100  
Split 116 94 93 88
After circulatory death 60 98 91 86  
Liver transplant Heterotopic 4 100 67  0.001
Orthotopic 2857 92 89 81
aLog-rank P value for effect over 8 y.
bBody mass index was defined as underweight: <18.5 kg/m2, normal weight: 18.5–24.9 kg/m2, overweight: 25.0–29.9 kg/m2, and obesity: ≥30 kg/m2.
cLiver transplant urgency was determined by the treating physician and indicated on the questionnaire by “yes” or “no” tick box.
dUNOS status: 1. Hospitalized in the intensive care unit, 2. Continuous hospitalization, 3. Continuous medical care, 4. At home with normal function.
HBsAg, hepatitis B virus surface antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IR, immediate release; MELD, Model for 
End-stage Liver Disease; PR, prolonged release; UNOS, United Network for Organ Sharing.
TABLE 4.
Multivariate analyses of risk factors for reduced graft and patient survival for the propensity score–matched patients
Risk factors at first transplant Risk ratio 95% Confidence interval P
Graft survival    
 Recipient anti-HCV serology positive 2.05 1.66-2.54 <0.001
 Recipient age ≥55 y 1.74 1.43-2.11 <0.001
 UNOS statusa 1 or 2 1.69 1.35-2.11 <0.001
 Serum creatinine concentration ≥2 mg/dL 1.66 1.18-2.35 0.004
 IR tacrolimus immunotherapy 1.49 1.14-1.96 0.0038
 Donor age ≥50 y 1.35 1.09-1.66 0.0052
Patient survival    
 Recipient anti-HCV serology positive 1.91 1.52-2.40 <0.001
 Serum creatinine concentration ≥2 mg/dL 1.90 1.33-2.71 <0.001
 UNOS statusa 1 or 2 1.89 1.49-2.39 <0.001
 Recipient age ≥55 y 1.74 1.41-2.16 <0.001
 IR tacrolimus immunotherapy 1.40 1.05-1.86 0.0215
 HCC (primary or secondary disease) 1.35 1.07-1.69 0.0109
 Donor age ≥50 y 1.33 1.07-1.66 0.0110
aUNOS status 1: Hospitalized in the intensive care unit; 2: Continuous hospitalization. N = 3883.
HCC, hepatocellular carcinoma; HCV, hepatitis C virus; IR, immediate release; UNOS, United Network for Organ Sharing.
1.91; 95% CI, 1.52-2.40; P < 0.001), serum creatinine 
concentration ≥2 mg/dL (risk ratio, 1.90; 95% CI, 1.33-
2.71; P < 0.001), UNOS status 1 or 2 (risk ratio, 1.89; 
95% CI, 1.49-2.39; P < 0.001), recipient age ≥50 years 
(risk ratio, 1.74; 95% CI, 1.41-2.16; P < 0.001), HCC as 
primary or secondary disease (risk ratio, 1.35; 95% CI, 
1.07-1.69; P = 0.01), and donor age ≥50 years (risk ratio, 
1.33; 95% CI, 1.07-1.66; P = 0.01).
Kaplan-Meier Analyses and Number of Patients 
Needed to Treat to Avoid 1 Graft Loss
Kaplan-Meier analysis demonstrated significantly 
improved graft and patient survival over 4 years with PR 
versus IR tacrolimus (83% versus 77%; P = 0.005 and 
85% versus 80%; P = 0.017, respectively) (Figure 3). At 
year 4, a 6% and 5% improvement in graft and patient 
survival, respectively, was observed in the PR versus IR 
tacrolimus group. The number of patients needed to treat 
with PR versus IR tacrolimus to avoid 1 graft loss in 4 
years was 14.3 patients (95% CI, 9.7-27.3).
Analysis of Crossover Groups
In the nonconverted patients over the study period, graft 
and patient survival were significantly higher with (induc-
tion-last follow-up immunosuppressive regimen available) 
PR-PR than with IR-IR tacrolimus (88% versus 82% at 4 y; 
P = 0.019 and 89% versus 83% at 4 y; P = 0.047, respec-
tively) (Figure 4). Patients converted from IR to PR tac-
rolimus after 1 month had a significantly higher graft and 
patient survival rate compared with patients who were 
started on and still receiving PR tacrolimus at the last 
follow-up (92% versus 88% at 4 y; P = 0.019 and 94% 
versus 89% at 4 y; P = 0.004, respectively) or started on 
and still receiving IR tacrolimus at the last follow-up (P < 
0.001 for both).
Causes of Graft Loss and Mortality
The most common cause of graft loss was infection in 
both groups (Table 5). Over 8 years of treatment, the pro-
portion of patients with bacterial infection that resulted 
in graft loss was higher with PR versus IR tacrolimus 
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(17.2% versus 9.2%, respectively; P = 0.031) (Table  5). 
Compared with patients receiving IR tacrolimus, “other” 
causes of graft loss were less frequent in patients receiving 
PR tacrolimus (P = 0.01). However, there were no signifi-
cant differences between groups in the incidence of graft 
loss due to acute or chronic rejection, cardiovascular, or 
renal causes.
The most common cause of patient mortality was infec-
tion in both groups (Table 5). The proportion of patients 
with bacterial infection that resulted in patient death was 
similar with PR and IR tacrolimus (18.3% versus 10.4%, 
respectively; P = 0.057). “Other” causes of mortality were 
less frequent in patients receiving PR versus IR tacrolimus 
(P = 0.005). There were no significant differences between 
treatment groups in the proportion of patients with car-
diovascular or renal causes of mortality.
DISCUSSION
The initial ELTR study was the first large retrospective 
registry study in Europe, evaluating PR tacrolimus–based 
immunosuppression in primary liver transplantation.21 
The study showed that the use of IR tacrolimus was asso-
ciated with a higher risk of graft loss and patient death, 
compared with PR tacrolimus. Additionally, PR tacrolimus 
significantly improved graft and patient survival over 3 
years posttransplantation, compared with the IR formula-
tion.21 However, the cohort size was relatively limited, as 
was the length of follow-up.
This extension to the ELTR study, reporting up to 8-year 
data from adult primary liver transplant recipients, con-
firmed that PR tacrolimus was associated with improved 
graft and patient survival (over 4 y posttransplantation), 
compared with IR tacrolimus. Consistent with Adam et 
al,21 IR tacrolimus was an independent risk factor for graft 
loss and mortality over 8 years of treatment. In addition 
to the longer time period assessed, the number of patients 
included in the current study exceeded 13 000, compared 
with the 4367 patients included in the initial ELTR study.21 
This provided enhanced statistical robustness, increasing 
the reliability of the results.
Univariate and multivariate analyses substantiated 
the independent prognostic value of typical risk factors, 
FIGURE 3. Kaplan-Meier analyses of (A) graft and (B) patient survival over 4 y of treatment with prolonged-release (PR) tacrolimus 
compared with immediate-release (IR) tacrolimus for the propensity score–matched patients.
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including donor age (≥50 y), recipient viral status (HCV 
positivity), and UNOS status 1 or 2 in impairing month 
1 to year 8 graft and patient survival.25,26 As reported by 
Adam et al,21 IR tacrolimus was also identified in this study 
as a significant predictor of graft loss and patient death 
in univariate analyses. Furthermore, after accounting for 
differences in baseline characteristics between treatment 
groups, IR tacrolimus formulation remained a significant 
FIGURE 4. Kaplan-Meier analyses of (A) graft and (B) patient survival over 4 y of treatment in crossover groups for the propensity 
score–matched patients. IR, immediate release; PR, prolonged release.






























































Causes of graft loss and mortality over 8 years of treatment for the propensity score–matched patients
Category Type
Graft loss, n (%)  Mortality, n (%)  
All (n = 3006) PR tacrolimus (n = 1002) IR tacrolimus (n = 2004) Pa All (n = 3006) PR tacrolimus (n = 1002) IR tacrolimus (n = 2004) Pa
Overall  408 93 315 – 351 82 269 –
Technical complications All 44 (10.8) 12 (12.9) 32 (10.2) 0.45 19 (5.4) 6 (7.3) 13 (4.8) 0.38
Biliary 21 (5.2) 6 (6.5) 15 (4.8) 0.39 12 (3.4) 4 (4.9) 8 (3.0) 0.41
Vascular 24 (5.9) 6 (6.5) 18 (5.7) 0.79 8 (2.3) 2 (2.4) 6 (2.2) 1.00
Rejection All 16 (3.9) 3 (3.2) 13 (4.1) 1.00 8 (2.3) 2 (2.4) 6 (2.2) 1.00
Acute 5 (1.2) 1 (1.1) 4 (1.3) 1.00 3 (0.9) 1 (1.2) 2 (0.7) 0.55
Chronic 11 (2.7) 2 (2.2) 9 (2.9) 1.00 5 (1.4) 1 (1.2) 4 (1.5) 1.00
Nontumoral recurrence  76 (18.6) 22 (23.7) 54 (17.1) 0.16 57 (16.2) 19 (23.2) 38 (14.1) 0.06
Other liver complications  13 (3.2) 3 (3.2) 10 (3.2) 1.00 12 (3.4) 3 (3.7) 9 (3.4) 1.00
Tumor Tumor recurrence 49 (12.0) 13 (14.0) 36 (11.4) 0.51 48 (13.7) 13 (15.9) 35 (13.0) 0.51
De novo tumor 50 (12.3) 10 (10.8) 40 (12.7) 0.62 50 (14.2) 10 (12.2) 40 (14.9) 0.54
De novo tumor 
(lymph)
3 (0.7) 1 (1.1) 2 (0.6) 0.54 3 (0.9) 1 (1.2) 2 (0.7) 0.55
Infection Overall 109 (26.7) 28 (30.1) 81 (25.7) 0.40 107 (30.5) 27 (32.9) 80 (29.7) 0.58
Bacterial 45 (11.0) 16 (17.2) 29 (9.2) 0.031 43 (12.3) 15 (18.3) 28 (10.4) 0.057
Viral 1 (0.2) 0 1 (0.3) 1.00 1 (0.3) 0 1 (0.4) 1.00
Fungal 2 (0.5) 1 (1.1) 1 (0.3) 0.40 2 (0.6) 1 (1.2) 1 (0.4) 0.41
Undefined 67 (16.4) 13 (14.0) 54 (17.1) 0.47 66 (18.8) 12 (14.6) 54 (20.1) 0.27
General Gastrointestinal 13 (3.2) 3 (3.2) 10 (3.2) 1.00 13 (3.7) 3 (3.7) 10 (3.7) 1.00
Cardiovascular 18 (4.4) 5 (5.4) 13 (4.1) 0.57 18 (5.1) 5 (6.1) 13 (4.8) 0.58
Cerebrovascular 13 (3.2) 6 (6.5) 7 (2.2) 0.08 13 (3.7) 6 (7.3) 7 (2.6) 0.09
Renal 15 (3.7) 3 (3.2) 12 (3.8) 1.00 15 (4.3) 3 (3.7) 12 (4.5) 1.00
Pulmonary 31 (7.6) 7 (7.5) 24 (7.6) 0.98 31 (8.8) 7 (8.5) 24 (8.9) 0.91
Other  66 (16.2) 7 (7.5) 59 (18.7) 0.010 62 (17.7) 6 (7.3) 56 (20.8) 0.005
Social cause  3 (0.7) 1 (1.1) 2 (0.6) 0.54 3 (0.9) 1 (1.2) 2 (0.7) 0.55
Suicide  1 (0.2) 0 1 (0.3) 1.00 1 (0.3) 0 1 (0.4) 1.00
a
P value for Mantel-Haenszel chi-square test between treatment cohort comparisons or Fisher exact test, as appropriate. Data are presented for up to 3 causes of graft loss or patient mortality for each patient.
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predictor of graft and patient loss, in both univariate and 
multivariate analyses.
In the previous ELTR study, improvements in graft 
and patient survival with PR versus IR tacrolimus were 
observed as early as 3 months after transplantation and 
continued over 3 years.21 Our current data demonstrate 
that the survival benefit associated with PR tacrolimus 
continues over 4 years of treatment. Furthermore, while 
improved 3-year patient survival with PR versus IR tac-
rolimus did not reach statistical significance for the 
unmatched patient cohort in the initial ELTR study,21 the 
benefit was statistically significant by year 4 in our current 
study. Indeed, there was a 5% and 4% graft and patient 
survival advantage, respectively, by year 4 with the PR ver-
sus IR formulation. The difference between the PR and IR 
groups for graft and patient survival rates also seemed to 
increase with time.
Consistent with data reported in a 4-year follow-up of 
de novo liver transplant recipients from a phase II study,27 
PR tacrolimus was associated with 4-year graft and patient 
survival rates of ~90%. As a complement to our previous 
study, we also evaluated the impact of crossover changes 
from IR to PR and vice versa after 1 month of induction 
therapy with regards to graft and patient outcomes. Both 
graft and patient survival were higher in patients who con-
verted from IR to PR tacrolimus, compared with those who 
received induction PR tacrolimus and were still receiving 
PR tacrolimus at last follow-up. Although the cause of this 
is unclear, the data suggest that the use of PR tacrolimus 
at last follow-up therapy is associated with improved out-
comes, irrespective of the timing of conversion. The trans-
plant community is now interested in identifying whether 
earlier conversion (<6 mo after liver transplantation) from 
IR to PR tacrolimus is associated with better outcomes 
than conversion >6 months posttransplantation.28
The survival advantages observed in patients treated 
with PR versus IR tacrolimus reported at 3 years in Adam 
et al,21 and at 4 years in this study were not observed in 
short-term, randomized, controlled trials. For example, 
Trunečka et al29 reported 12-month graft survival rates of 
85.3% and 85.6%, and patient survival rates of 89.2% and 
90.8%, with PR and IR tacrolimus, respectively. The poten-
tial survival advantages associated with PR tacrolimus 
in de novo liver transplant recipients may, therefore, not 
become apparent until beyond 1-year posttransplantation.
In an independent editorial that accompanied the initial 
ELTR study, Asrani and O’Leary30 considered the poten-
tial mechanisms underlying the improvement in long-term 
graft and patient survival with PR versus IR tacrolimus-
based immunosuppression. Compared with IR tacrolimus, 
PR formulation reduces variability of tacrolimus expo-
sure19,31 and offers a simpler regimen comprising a single, 
morning dose,12 which can improve medication adher-
ence.17,18 Indeed, in an expert literature review, improved 
adherence with treatment is highlighted as a main advan-
tage of PR versus IR tacrolimus.28 Given that high intra-
patient variability in tacrolimus exposure and medication 
nonadherence have been associated with poor transplant 
outcomes,8,20 PR tacrolimus may improve long-term graft 
and patient survival compared with the IR formulation.
As observed in the initial ELTR study,21 the overall pro-
portion of patients with graft loss was lower in the PR 
versus IR tacrolimus group. The reasons for graft loss and 
mortality were generally comparable between groups in 
this study and, consistent with the previous ELTR study, 
infections were the most frequent cause.21
In this study, not all factors could be controlled by the 
transplant team to improve outcomes. Only the type of 
preservation solution, the ischemia time, and the immuno-
suppressive regimen used could be altered, as donor and 
recipient characteristics cannot be changed in the MELD 
allocation system used in most countries. Therefore, it 
is important to consider the numbers of patients needed 
to treat with PR tacrolimus to avoid 1 graft loss. In this 
study, 14.3 patients needed to be treated with PR versus 
IR tacrolimus to avoid 1 graft loss in 4 years. These data 
are consistent with those of Muduma et al,32 who devel-
oped a model using UK liver transplant data and showed 
that, over a 3-year time period, 1 graft would be saved for 
every 14 patients treated with PR versus IR tacrolimus, 
with minimal impact on costs. To place these data in clini-
cal context, 15 patients needed to be treated with nicotine 
replacement therapy for 1 patient to cease smoking,33 20 
required treatment with calcium and vitamin D for 3 years 
to prevent 1 hip fracture,34 23 required treatment with flu 
vaccine to prevent 1 flu episode,35 and 35 needed primary 
treatment with statins for 5 years to prevent a cardiac 
event.36
Despite the improvements to our study design and ana-
lytical methods, any conclusions drawn from our findings 
must be made within the context of the limitations of our 
study, which have been described in detail previously.21 
These include the retrospective nature of the study and the 
long period over which data were collected, which may be 
associated with changes in clinical practice. Furthermore, 
our study design carries a risk of bias in terms of patient 
and treatment selection. To control for these differences, 
propensity score matching was undertaken against a larger 
number of characteristics compared with the initial ELTR 
study. However, it is recognized that propensity score 
matching can only be used to balance measured variables 
and cannot entirely exclude inherent differences, such as 
socioeconomic factors, ethnicity, or other unknown vari-
ables. A major limitation concerns the lack of data on 
drug exposure, as the dose and trough levels of tacroli-
mus were not captured in the ELTR; it is also not known 
which IR tacrolimus preparation patients were receiving. 
Despite these limitations, to our knowledge, we report on 
the largest population of liver transplant recipients to date, 
comparing the impact of PR and IR tacrolimus adminis-
tration. Furthermore, this analysis builds on our previous 
publication by including a 3-fold larger cohort, provid-
ing extended follow-up, evaluating the impact of crosso-
ver between IR and PR tacrolimus therapy, and reporting 
the clinical implication of the results in terms of number 
needed to treat to avoid 1 graft loss.
Our results, based on up to 8-year data, confirm obser-
vations from the initial 3-year study21 that PR tacroli-
mus-based immunosuppression can improve long-term 
outcomes in liver transplantation compared with IR 
tacrolimus. Furthermore, IR tacrolimus–based immuno-
suppression is a significant predictor of long-term graft 
loss and patient mortality. Conversion from IR to PR 
tacrolimus after 1 month was also associated with a bet-
ter outcome compared with maintaining patients on IR 
tacrolimus–based immunosuppression, or starting and 
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maintaining patients on PR tacrolimus–based immunosup-
pression. Importantly, our findings confirm that PR tacroli-
mus continues to provide ongoing benefits for graft and 
patient survival beyond 3 years posttransplantation.
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